Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Net Cash Flow (2016 - 2025)

Organogenesis Holdings (ORGO) has 10 years of Net Cash Flow data on record, last reported at $30.0 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 27.33% year-over-year to $30.0 million; the TTM value through Dec 2025 reached -$41.8 million, down 231.46%, while the annual FY2025 figure was -$41.8 million, 231.46% down from the prior year.
  • Net Cash Flow reached $30.0 million in Q4 2025 per ORGO's latest filing, up from -$9.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $41.2 million in Q4 2024 and bottomed at -$36.8 million in Q2 2025.
  • Average Net Cash Flow over 5 years is $476250.0, with a median of $612000.0 recorded in 2023.
  • Peak YoY movement for Net Cash Flow: skyrocketed 1116.13% in 2024, then tumbled 3353.67% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $11.8 million in 2021, then tumbled by 140.08% to -$4.7 million in 2022, then surged by 216.53% to $5.5 million in 2023, then skyrocketed by 647.78% to $41.2 million in 2024, then decreased by 27.33% to $30.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $30.0 million in Q4 2025, -$9.4 million in Q3 2025, and -$36.8 million in Q2 2025.